Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapyopen access
- Authors
- Park, Jong-Ho; Ovbiagele, Bruce
- Issue Date
- 2020
- Publisher
- JAPAN ATHEROSCLEROSIS SOC
- Keywords
- Lipid; Statin; Stroke; HDL; Triglycerides; Dyslipidemia
- Citation
- JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, v.27, no.2, pp.144 - 154
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
- Volume
- 27
- Number
- 2
- Start Page
- 144
- End Page
- 154
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146500
- DOI
- 10.5551/jat.49304
- ISSN
- 1340-3478
- Abstract
- Aims: Low-density lipoprotein (LDL)-lowering statin therapy is an established secondary stroke prevention strategy. However, the differential impact of key non-LDL levels on recurrent stroke risk, while on lipid-modifying therapy (LT), remains unclear.
Methods: We analyzed the dataset of a multicenter trial involving 3640 recent (<4 months) noncardioembolic stroke patients followed for 2 years. Participants were categorized into four groups of presumed improving lipid profile: level 0, no LT prescribed; level I, LT use with low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL for men; <50 mg/dL for women); level II, LT use with high HDL-C (≥ 40 mg/dL and ≥ 50 mg/dL, respectively); and level III, level II with low triglycerides (<150 mg/dL). Independent associations of LT category with stroke, major vascular events (MVEs; stroke/coronary heart disease/vascular death), and all-cause death were assessed.
Results: LTs were mostly statins (>95%). The unadjusted recurrent stroke rate declined with LT category level (9.2% for level 0; 8.4% for level I; 7.5% for level II; and 5.7% for level III). Compared with level 0, the adjusted hazard ratio of stroke for level I was 0.78 (95% confidence interval (CI), 0.59–1.03), level II 0.80 (0.54–1.18), and level III 0.63 (0.43–0.91). Multivariable analyses of MVEs and all-cause death followed a similar pattern of declining risk with higher LT category level.
Conclusions: Compared with the nonuse of LT, there may be a hierarchy of residual vascular risk after stroke by non-LDL type and target, while on LT. Particularly, stroke patients with low HDL-C levels on LT may benefit from additional therapeutic strategies to improve their outcomes.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146500)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.